Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $58.00.

Several brokerages have recently issued reports on TWST. Robert W. Baird increased their price objective on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Guggenheim increased their price objective on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Barclays increased their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Evercore increased their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 4,000 shares of the stock in a transaction on Friday, April 17th. The shares were sold at an average price of $60.00, for a total transaction of $240,000.00. Following the completion of the transaction, the chief financial officer owned 118,694 shares in the company, valued at approximately $7,121,640. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jan Johannessen sold 12,000 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total transaction of $673,440.00. Following the transaction, the director owned 17,754 shares of the company’s stock, valued at $996,354.48. The trade was a 40.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 46,551 shares of company stock valued at $2,566,533 in the last three months. 3.08% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Stifel Financial Corp boosted its holdings in Twist Bioscience by 3.6% during the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after purchasing an additional 271 shares during the last quarter. D.A. Davidson & CO. boosted its holdings in Twist Bioscience by 1.2% during the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after purchasing an additional 305 shares during the last quarter. CWM LLC boosted its holdings in Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after purchasing an additional 407 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares during the last quarter.

Twist Bioscience Stock Down 1.1%

Shares of TWST stock opened at $64.17 on Friday. The firm has a fifty day moving average of $53.74 and a 200-day moving average of $44.02. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 12-month low of $23.30 and a 12-month high of $66.94. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of -48.25 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The company had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. During the same period in the prior year, the company earned ($0.66) EPS. The firm’s revenue was up 19.3% on a year-over-year basis. As a group, equities research analysts predict that Twist Bioscience will post -1.86 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.